{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:18:08Z","timestamp":1790561888529,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rpth.2024.102424","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T03:30:33Z","timestamp":1714102233000},"page":"102424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use"],"prefix":"10.1016","volume":"8","author":[{"given":"Candrika D.","family":"Khairani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Bejjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Assi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Porio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azita H.","family":"Talasaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102424_bib1","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102424_bib2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and\u00a0acute coronary syndromes: ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease position paper","volume":"59","author":"De Caterina","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102424_bib3","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102424_bib4","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2024.102424_bib5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102424_bib6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102424_bib7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102424_bib8","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102424_bib9","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102424_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102424_bib11","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102424_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102424_bib13","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102424_bib14","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.rpth.2024.102424_bib15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102424_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102424_bib17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2024.102424_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0961203319889156","article-title":"Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study","volume":"29","author":"Malec","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2024.102424_bib19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2024.102424_bib20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study","volume":"121","author":"Ageno","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102424_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40814-020-00594-1","article-title":"A\u00a0single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome","volume":"6","author":"Legault","year":"2020","journal-title":"Pilot Feasibility Stud"},{"key":"10.1016\/j.rpth.2024.102424_bib22","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2024.102424_bib23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102424_bib24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2024.102424_bib25","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102424_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102424_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1160\/TH13-12-1047","article-title":"Only high levels of dabigatran attenuate catheter thrombosis in\u00a0vitro and in rabbits","volume":"112","author":"Yau","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102424_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2017.04.003","article-title":"A\u00a0prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)","volume":"162","author":"Davies","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102424_bib57a","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2022-159135","article-title":"A prospective study of apixaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients: catheter 3","volume":"140","author":"Kovacs","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102424_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/STROKEAHA.121.037541","article-title":"Direct oral anticoagulants versus warfarin in the treatment of cerebral venous thrombosis (ACTION-CVT): a multicenter international study","volume":"53","author":"Yaghi","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102424_bib31","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamaneurol.2019.2764","article-title":"Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial","volume":"76","author":"Ferro","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.rpth.2024.102424_bib29","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/bloodadvances.2022007397","article-title":"Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study","volume":"6","author":"Ageno","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102424_bib32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2022.1292","article-title":"Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review","volume":"7","author":"Bikdeli","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.rpth.2024.102424_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/07853890.2014.982064","article-title":"Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials","volume":"47","author":"Di Minno","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.rpth.2024.102424_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH16-02-0087","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102424_bib35","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jth.15823","article-title":"Direct oral anticoagulants after bariatric surgery-what is the evidence?","volume":"20","author":"Leong","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102424_bib36","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102424_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.15241","article-title":"Efficacy and safety of rivaroxaban for postoperative thromboprophylaxis in patients after bariatric surgery: a randomized clinical trial","volume":"6","author":"Kr\u00f6ll","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2024.102424_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2018.04.008","article-title":"Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: a systemic review and meta-analysis","volume":"166","author":"Yamashita","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102424_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12959-015-0035-3","article-title":"Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism \u2013 the J-EINSTEIN DVT and PE program","volume":"13","author":"Yamada","year":"2015","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2024.102424_bib40","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/jth.13055","article-title":"Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial","volume":"13","author":"Nakamura","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102424_bib41","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/AOG.0000000000000277","article-title":"Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta","volume":"123","author":"Bapat","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.rpth.2024.102424_bib42","doi-asserted-by":"crossref","first-page":"710.e1","DOI":"10.1016\/j.ajog.2015.06.065","article-title":"Rivaroxaban transfer across the dually perfused isolated human placental cotyledon","volume":"213","author":"Bapat","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.rpth.2024.102424_bib43","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1016\/S2352-3026(20)30327-6","article-title":"Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study","volume":"7","author":"Beyer-Westendorf","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2024.102424_bib44","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(21)00682-6","article-title":"Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss","volume":"397","author":"Quenby","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102424_bib45","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2020006231","article-title":"Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?","volume":"136","author":"Zhao","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102424_bib46","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1002\/ajh.25652","article-title":"Investigation of dabigatran secretion into breast milk: implications for oral thromboprophylaxis in post-partum women","volume":"95","author":"Ayuk","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2024.102424_bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2024.102424_bib48","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102424_bib50","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102424_bib52","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2024.102424_bib49","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation","volume":"18","author":"Di Nisio","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102424_bib51","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/STR.0b013e31820a8364","article-title":"Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Saposnik","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2024.102424_bib54","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ejh.13338","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients: the EVE trial","volume":"104","author":"McBane","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2024.102424_bib55","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1055\/a-1646-2244","article-title":"Extended-duration low-intensity apixaban to prevent recurrence in patients with provoked venous thromboembolism and enduring risk factors: rationale and design of the HI-PRO trial","volume":"122","author":"Bikdeli","year":"2022","journal-title":"Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T05:32:42Z","timestamp":1722144762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924001134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2475037924001134"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102424","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102424"}}